Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) – Pipeline Review, 2019

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content:

1. Introduction

    1.1. Report Overview

2. Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Overview

3. Executive Summary

4. Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3): Pipeline Assessment

    4.1. By Stage of Development

    4.2. By Route of Administration

    4.3. By Drug Class

    4.4. By Molecule Type

    4.5. By Therapy Area / Indication

    4.6. By Drug Target

    4.7. By Sponsor

5. Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3): Company & Drug Profiles

    5.1. Clinical Stage

        5.1.1. IMP321 – Immutep S.A.

            5.1.1.1. Company Overview

            5.1.1.2. Product Description

            5.1.1.3. R&D Status & Development Activities

            5.1.1.4. Mechanism of Action

            5.1.1.5. Molecule Type

            5.1.1.6. Stage of Development

            5.1.1.7. Indications

            5.1.1.8. Route of Administration

            5.1.1.9. Funding

        5.1.2. XmAb22841 – Xencor

            5.1.2.1. Company Overview

            5.1.2.2. Product Description

            5.1.2.3. R&D Status & Development Activities

            5.1.2.4. Mechanism of Action

            5.1.2.5. Molecule Type

            5.1.2.6. Stage of Development

            5.1.2.7. Indications

            5.1.2.8. Route of Administration

            5.1.2.9. Funding

        5.1.3. LAG525 – Novartis AG

            5.1.3.1. Company Overview

            5.1.3.2. Product Description

            5.1.3.3. R&D Status & Development Activities

            5.1.3.4. Mechanism of Action

            5.1.3.5. Molecule Type

            5.1.3.6. Stage of Development

            5.1.3.7. Indications

            5.1.3.8. Route of Administration

            5.1.3.9. Funding

        5.1.4. Others

    5.2. Preclinical

        5.2.1. Company Overview

        5.2.2. Product Description

        5.2.3. R&D Status & Development Activities

        5.2.4. Mechanism of Action

        5.2.5. Molecule Type

        5.2.6. Indications

        5.2.7. Route of Administration

        5.2.8. Funding

6. Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3): An Overview on Dormant & Discontinued Pipeline Candidates

    6.1. Overview

    6.2. Product Description

    6.3. Reason for Discontinuation

7. Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3): Additional Key Insights

    7.1. Comparative Analysis of Different Sponsors

    7.2. Current Market Scenario: Role of Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) in the development of oncology therapeutics

8. Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3): News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.